3,10-diazaphenanthrene | 316-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3,10-diazaphenanthrene
• 英文别名: 3,10-Diazaphenanthren；Benzo[c][1,6]naphthyridine
• CAS: 316-92-7
• 化学式: C₁₂H₈N₂
• 分子量: 180.209
• InChiKey: BYXCINYJZUMIJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5,6,6a,7,8,9,10,10a-octahydrobenzo[c][1,6]naphthyridine 以37%的产率得到
  参考文献：
  名称：

  NINOMIYA I.; KIGUCHI T.; YAMAUCHI S.; NAITO T., J. CHEM. SOC. PERKIN TRANS., PART 1 , 1976, NO 17, 1861-1865

  摘要：

  DOI：

文献信息

• [EN] NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS ÉLECTROLUMINESCENTS ORGANIQUES ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LES UTILISANT
  申请人：ROHM & HAAS ELECT MAT

  公开号：WO2011105700A1

  公开（公告）日：2011-09-01

  Provided are novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same. Since the organic electroluminescent compounds exhibit high luminous efficiency in blue color, and excellent life property of the material, they may be used to manufacture OLEDs having very good operation life.

  提供了新颖的有机电致发光化合物，以及包含这些化合物的有机电致发光器件。由于这些有机电致发光化合物在蓝色方面表现出高发光效率，并且材料具有优秀的寿命特性，因此它们可以用于制造具有非常良好使用寿命的OLED。
• Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use
  申请人：——

  公开号：US20040087591A1

  公开（公告）日：2004-05-06

  The invention describes novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

  该发明描述了一种新型组合物，其中包含至少一种磷酸二酯酶抑制剂，以及至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或一种或多种血管活性剂的化合物。该发明还提供了治疗或预防男性和女性性功能障碍、增强男性和女性性反应以及治疗或预防由环磷鸟苷3′，5′-单磷酸（cGMP）代谢增加引起的疾病的方法，如高血压、肺动脉高压、充血性心力衰竭、肾功能衰竭、心肌梗塞、稳定、不稳定和变异性（普林兹梅塔尔）心绞痛、动脉粥样硬化、心脏水肿、肾功能不全、肾病性水肿、肝性水肿、中风、哮喘、支气管炎、慢性阻塞性肺疾病（COPD）、囊性纤维化、痴呆、免疫缺陷、早产、痛经、良性前列腺增生（BPH）、膀胱出口梗阻、失禁、血管通畅度降低的疾病，例如经皮冠状动脉成形术后（post-PTCA）、外周血管疾病、变应性鼻炎、青光眼以及肠道运动障碍等疾病的特征性障碍。
• PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
  申请人：Blend Therapeutics

  公开号：US20140088066A1

  公开（公告）日：2014-03-27

  The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same.

  本公开涉及新型药物组合物，包括与铂类活性药物相关联、连接或封装的纳米颗粒。铂类药物从纳米颗粒中以受控的方式释放。还考虑了制备纳米颗粒的方法，以及在治疗或预防疾病或病症中使用它们的方法。其中一种实施形式涉及苯并芘铂纳米颗粒及其制备和使用方法。
• HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION
  申请人：TOSOH CORPORATION

  公开号：US20160056388A1

  公开（公告）日：2016-02-25

  A novel heterocyclic compound for an organic electroluminescent device excellent in long service life and light-emitting characteristics is provided. A cyclic azine compound has at least one substituent (substituent B) selected from a specific group.

  提供一种新的杂环化合物，用于有机电致发光器件，具有长寿命和发光特性优异。该环状腈化合物至少具有来自特定群组的一个取代基（取代基B）。
• Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof
  申请人：PLACON THERAPEUTICS, INC.

  公开号：US10472380B2

  公开（公告）日：2019-11-12

  The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.

  本公开涉及具有杂环配体的新型铂组合物和纳米颗粒，以及使用此类组合物（如用于治疗癌症）的方法。